HER-2 and choice of adjuvant chemotherapy in breast cancer.
The amplification or overexpression of HER-2 is a recognized prognostic marker that is associated with poor survival for patients with node-positive breast cancer. Several studies have demonstrated that HER-2 may serve to direct the selection of optimal adjuvant chemotherapy. This article provides a critical review of the studies that offer evidence for the role of HER-2 as a predictor of response to chemotherapy.
Paik
S
S
Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA.
Park
C
C
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D005260:Female; D018734:Genes, erbB-2; D006801:Humans